Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen
| Autor: | Maria K. Angelopoulou, Penelope Korkolopoulou, Xanthi Yiakoumis, Pantelis Tsirkinidis, Maria Athanasoulia, Georgios Georgiou, Theodoros P. Vassilakopoulos, Stavroula Masouridis, Christina Kalpadakis, Panayiotis Panayiotidis, Styliani I. Kokoris, Vassiliki Pappis, Marina P. Siakantaris, Sotirios Sachanas, Flora N. Kontopidou, Gerassimos A. Pangalis, Maria Moschogiannis |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Lymphoma Mantle-Cell Gastroenterology Drug Administration Schedule Antibodies Monoclonal Murine-Derived International Prognostic Index Quality of life immune system diseases hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Aged 80 and over Chlorambucil Dose-Response Relationship Drug business.industry Remission Induction Antibodies Monoclonal Hematology Middle Aged medicine.disease Neoadjuvant Therapy Surgery First line treatment Regimen Treatment Outcome Oncology Toxicity Rituximab Mantle cell lymphoma Female business medicine.drug Follow-Up Studies |
| Zdroj: | Leukemialymphoma. 52(3) |
| ISSN: | 1029-2403 |
| Popis: | The optimal treatment approach for patients with mantle cell lymphoma (MCL) is not well defined. Intensive therapeutic regimens result in high response rates and prolonged progression-free survival but at the expense of significant toxicity. We report here our results of the administration of rituximab plus chlorambucil (R-Chl) as first line treatment in patients with MCL. Twenty consecutively diagnosed patients were treated with this combination in which an induction and a maintenance arm were included. During induction, rituximab was administered at a dose of 375 mg/m(2) on day 1, while chlorambucil was given afterward at a dose of 10 mg/day for 10 consecutive days for eight cycles and then as a single agent for an additional four cycles. Maintenance consisted of rituximab administration every 2 months for 1 year. Most patients had indolent disease features such as a low mantle-cell international prognostic index (MIPI) score. The overall response rate was 95% (90% CR, 5% PR). Among patients in CR, 78% presented a molecular remission. The 3-year progression-free survival was 89%. There were no serious side effects. These results show that the R-Chl combination could be an effective therapeutic option as first line treatment in MCL, especially for patients with indolent disease characteristics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|